- Email: [email protected]
Process for the preparation of lyophilized, adsorbed polyvalent vaccines
Patent Report The (I) obtained is used as a vaccine in the prevention of footrot in sheep. 108-86
New DNA sequences containing pre-S(l) nucleotide sequence of hepatitis B virus and antigenic polypeptide useful in vaccine production
New pure mycobacterial A60 antigen and its active fragments from Mycobacterium bovis and Mycobacterium kansasii etc.; application for vaccine production and diagnosis
Asta Eur. 180 012; 7 June 1986
Anda Biologicals Eur. 184 511; 11 June 1986
Live vaccine for bovine babesiosis and method of preparation
A method for isolating the A60 antigen from the cytoplasm of a mycobacterium of supergroup CMN comprises (1) destroying the mycobacterial cell walls, (2) removing cell debris, preferably by centrifugation; (3) collecting the cyptoplasm containing supernatant; (4) exclusion chromatography on a gel and (5) collecting the exclusion peak containing pure A60. Step (4) is preferably carried out on a column of Sepharose 4B or 6B and the supernatant is preferably treated with RNAase or DNAase before this step. The isolated A60 can be reacted with a protease (or a chemical such as CNBr having similar activity) to produce immunologically active fragments. Antibodies (polyclonal or monoclonal) can be raised against such fragments. The antigen can be isolated from Mycobacterium scrofulaceum, Mycobacterium xenopi, Mycobacterium chelonei, Mycobacterium paratuberculosis, Mycobacterium leprae or most preferably Mycobacterium boris and Mycobacterium kansasii. These antigens are useful for diagnosis and may have potential for vaccine production. 109-86 Viruses with recombinant surface proteins useful in vaccine production
Salk Inst. Biotechnol.; Ind. Ass. US 4593 002; 3 June 1986 Virus is modified to give it a new biological function by inserting a foreign nucleotide base sequence into the viral genome at a location where such a sequence is expressed as an exposed segment of a surface viral protein which forms part of the coat of the modified virus. Preferably, the sequence is inserted into the genome by: (a) splicing a part of the genome containing part or more of the gene for the surface protein into a cloning vector; (b) infecting an organism with the vector to form multiple copies of the vector; (c) cleaving the splice cloning vector within the surface protein gene fragment; (d) linking foreign nucleotide base sequence to the cleaved ends of the fragment; (e) isolating the spliced part of the genome containing the foreign sequence from the cloning vector; and (f) joining the isolated genome portion with additional viral genome portions to create a functional viral genome. The recombinant virus is useful in vaccine production. Examples cite the use of vesticular-stomatis virus and polio virus. 110-86 Antigenic malaria protein derived from Plasmodium falciparum, Plasmodium vivax, Plasmodium ovalae or Plasmodium malariae
US Army US 6780 751; 18 March 1986
111-86
Non-reverting live vaccine prepared by transducing cells of a virulent pathogenic cellular microorganism
Leland Stanford Jr Univ. World 8603 123; 5 June 1986
112-86
Curators of Univ. Missouri US 4590 072; 20 May 1986
114-86
115-86
Preparation and use of enzyme-detergent extracted Streptococcus equi vaccine
Miles Laboratories US 4582 798; 15 April 1986
116-86
Toxoids of elastase of Pseudomonas aeruginosa origin
Toho Yakuhin Kogyo Kabushiki Kaisha US 4575 459; 11 March 1986 An inactivated, but still antigenic, form of a Pseudomonas aeruginosa elastase. The enzyme is inactivated by treatment with a synthetic peptide of chloroacetyl-N-hydroxy-L-leucylL-alanylglycinamide. 117-86 Synthetic antigenic peptide derived from hepatitis B surface antigen
New York Blood Center US 4575 459; 11 March 1986 A synthetic peptide having the amino acid sequence Arg-TrpMet-Met-Leu-Arg-Arg, in association with a carrier of some form. 118-86 Synthetic antigenic peptide derived from hepatitis B surface antigen
New York Blood Center US 4578 217; 25 March 1986 A synthetic peptide with the sequence Arg-Trp-Met-MetLeu-Arg-Arg. 119-86 Immunogenic protein or peptide complex, method of producing said complex and the use thereof as an immune stimulant and as a vaccine
Bror Morein US 4578 269; 25 March 1986
120-86
Process for the preparation of lyophilized, adsorbed polyvalent vaccines
Human Oltoanyagtermelo Es Kutato lntezet US 4578 270; 25 March 1986 A lyophilized, adsorbed, polyvalent vaccine against tetanus, diphtheria and pertussis. Concentrated antigen is adsorbed on aluminium hydroxide or aluminium phosphate, at a pH selected to assure at least 85% adsorption. A protective material, either a protein, polypeptide or polysaccharide, is added to the vaccine prior to it being freeze dried. 121-86 Mucoid exopolysaccharide vaccine against Pseudomonas aeruginosa
Live vaccine for cattle using a Salmonella dublin mutant defective in 50 MD plasmid
Brigham and Women's Hospital US 4578 458; 25 March 1986
Noriinsho Jpn. 1053 225; 17 March 1986
A polymer of mannuronic and guluronic acids bearing antigenic determinants of Pseudomonas aeruginosa 2192. 122-86
276
Vaccine, Vol. 4, December 1986
113-86
New DNA sequences containing pre-S(l) nucleotide sequence of hepatitis B virus and antigenic polypeptide useful in vaccine production
New pure mycobacterial A60 antigen and its active fragments from Mycobacterium bovis and Mycobacterium kansasii etc.; application for vaccine production and diagnosis
Asta Eur. 180 012; 7 June 1986
Anda Biologicals Eur. 184 511; 11 June 1986
Live vaccine for bovine babesiosis and method of preparation
A method for isolating the A60 antigen from the cytoplasm of a mycobacterium of supergroup CMN comprises (1) destroying the mycobacterial cell walls, (2) removing cell debris, preferably by centrifugation; (3) collecting the cyptoplasm containing supernatant; (4) exclusion chromatography on a gel and (5) collecting the exclusion peak containing pure A60. Step (4) is preferably carried out on a column of Sepharose 4B or 6B and the supernatant is preferably treated with RNAase or DNAase before this step. The isolated A60 can be reacted with a protease (or a chemical such as CNBr having similar activity) to produce immunologically active fragments. Antibodies (polyclonal or monoclonal) can be raised against such fragments. The antigen can be isolated from Mycobacterium scrofulaceum, Mycobacterium xenopi, Mycobacterium chelonei, Mycobacterium paratuberculosis, Mycobacterium leprae or most preferably Mycobacterium boris and Mycobacterium kansasii. These antigens are useful for diagnosis and may have potential for vaccine production. 109-86 Viruses with recombinant surface proteins useful in vaccine production
Salk Inst. Biotechnol.; Ind. Ass. US 4593 002; 3 June 1986 Virus is modified to give it a new biological function by inserting a foreign nucleotide base sequence into the viral genome at a location where such a sequence is expressed as an exposed segment of a surface viral protein which forms part of the coat of the modified virus. Preferably, the sequence is inserted into the genome by: (a) splicing a part of the genome containing part or more of the gene for the surface protein into a cloning vector; (b) infecting an organism with the vector to form multiple copies of the vector; (c) cleaving the splice cloning vector within the surface protein gene fragment; (d) linking foreign nucleotide base sequence to the cleaved ends of the fragment; (e) isolating the spliced part of the genome containing the foreign sequence from the cloning vector; and (f) joining the isolated genome portion with additional viral genome portions to create a functional viral genome. The recombinant virus is useful in vaccine production. Examples cite the use of vesticular-stomatis virus and polio virus. 110-86 Antigenic malaria protein derived from Plasmodium falciparum, Plasmodium vivax, Plasmodium ovalae or Plasmodium malariae
US Army US 6780 751; 18 March 1986
111-86
Non-reverting live vaccine prepared by transducing cells of a virulent pathogenic cellular microorganism
Leland Stanford Jr Univ. World 8603 123; 5 June 1986
112-86
Curators of Univ. Missouri US 4590 072; 20 May 1986
114-86
115-86
Preparation and use of enzyme-detergent extracted Streptococcus equi vaccine
Miles Laboratories US 4582 798; 15 April 1986
116-86
Toxoids of elastase of Pseudomonas aeruginosa origin
Toho Yakuhin Kogyo Kabushiki Kaisha US 4575 459; 11 March 1986 An inactivated, but still antigenic, form of a Pseudomonas aeruginosa elastase. The enzyme is inactivated by treatment with a synthetic peptide of chloroacetyl-N-hydroxy-L-leucylL-alanylglycinamide. 117-86 Synthetic antigenic peptide derived from hepatitis B surface antigen
New York Blood Center US 4575 459; 11 March 1986 A synthetic peptide having the amino acid sequence Arg-TrpMet-Met-Leu-Arg-Arg, in association with a carrier of some form. 118-86 Synthetic antigenic peptide derived from hepatitis B surface antigen
New York Blood Center US 4578 217; 25 March 1986 A synthetic peptide with the sequence Arg-Trp-Met-MetLeu-Arg-Arg. 119-86 Immunogenic protein or peptide complex, method of producing said complex and the use thereof as an immune stimulant and as a vaccine
Bror Morein US 4578 269; 25 March 1986
120-86
Process for the preparation of lyophilized, adsorbed polyvalent vaccines
Human Oltoanyagtermelo Es Kutato lntezet US 4578 270; 25 March 1986 A lyophilized, adsorbed, polyvalent vaccine against tetanus, diphtheria and pertussis. Concentrated antigen is adsorbed on aluminium hydroxide or aluminium phosphate, at a pH selected to assure at least 85% adsorption. A protective material, either a protein, polypeptide or polysaccharide, is added to the vaccine prior to it being freeze dried. 121-86 Mucoid exopolysaccharide vaccine against Pseudomonas aeruginosa
Live vaccine for cattle using a Salmonella dublin mutant defective in 50 MD plasmid
Brigham and Women's Hospital US 4578 458; 25 March 1986
Noriinsho Jpn. 1053 225; 17 March 1986
A polymer of mannuronic and guluronic acids bearing antigenic determinants of Pseudomonas aeruginosa 2192. 122-86
276
Vaccine, Vol. 4, December 1986
113-86